Christina E. Sparbier

Christina E. Sparbier

Auto-generated profile, based on publicly available information

Christina E. Sparbier

Peter MacCallum Cancer Centre, 305 Grattan Street, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC 3052, Australia

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 August 2017 in Nature
Verified
Journal Article
Closed access
MBMarian L. Burr
Marian L. Burr
CSChristina E. Sparbier
Christina E. Sparbier
YCYih-Chih Chan
Yih-Chih Chan
JWJames C. Williamson
James C. Williamson
KWKatherine Woods
Katherine Woods
MDMark A. Dawson
Mark A. Dawson

1 October 2019 in Cancer Cell
Verified
Journal Article
Open access
MBMarian L. Burr
Marian L. Burr
CSChristina E. Sparbier
Christina E. Sparbier
KCKah Lok Chan
Kah Lok Chan
YCYih-Chih Chan
Yih-Chih Chan
AKAriena Kersbergen
Ariena Kersbergen
MDMark A. Dawson
Mark A. Dawson
Loss of MHC class I (MHC-I) antigen presentation in cancer cells can elicit immunotherapy resistance. A genome-wide CRISPR/Cas9 screen identified an evolutionarily conserved function of polycomb repressive complex 2 (PRC2) that mediates coordinated transcriptional silencing of the MHC-I antigen processing pathway (MHC-I APP), promoting evasion of T cell-mediated immunity. MHC-I APP gene promoters in MHC-I low cancers harbor bivalent activating H3K4me3 and repressive H3K27me3 histone modifications, silencing basal MHC-I expression and restricting cytokine-induced upregulation. Bivalent chromatin at MHC-I APP genes is a normal developmental process active in embryonic stem cells and maintained during neural progenitor differentiation. This physiological MHC-I silencing highlights a conserved mechanism by which cancers arising from these primitive tissues exploit PRC2 activity to enable immune evasion.

29 August 2019
Verified
Journal Article
Open access
MBMarian Burr
Marian Burr
CSChristina E Sparbier
Christina E Sparbier
KCKah Lok Chan
Kah Lok Chan
YCYih-Chih Chan
Yih-Chih Chan
AKAriena Kersbergen
Ariena Kersbergen
MDMark A Dawson
Mark A Dawson
Loss of MHC class I (MHC-I) antigen presentation in cancer cells can elicit immunotherapy resistance. A genome-wide CRISPR/Cas9 screen identified an evolutionarily conserved function of polycomb repressive complex 2 (PRC2) that mediates coordinated transcriptional silencing of the MHC-I antigen processing pathway (MHC-I APP), promoting evasion of T-cell mediated immunity. MHC-I APP gene promoters in MHC-I low cancers harbor bivalent activating H3K4me3 and repressive H3K27me3 histone modifications, silencing basal MHC-I expression and restricting cytokine induced upregulation. Bivalent chromatin at MHC-I APP genes is a normal developmental process active in embryonic stem cells and maintained during neural progenitor differentiation. This physiological MHC-I silencing highlights a conserved mechanism by which cancers arising from these primitive tissues exploit PRC2 activity to enable immune evasion.